國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Efficacy of a Pseudomonas aeruginosa...

Scarff, Jennifer Mary.

Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice.
作者:	Scarff, Jennifer Mary.
面頁冊數:	182 p.
附註:	Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 1920.
附註:	Adviser: Joanna B. Goldberg.
Contained By:	Dissertation Abstracts International72-04B.
標題:	Biology, Microbiology.
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3445975
ISBN:	9781124501222

Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice.
Scarff, Jennifer Mary.

Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice. - 182 p.

Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 1920.

Thesis (Ph.D.)--University of Virginia, 2011.

Pseudomonas aeruginosa is an important opportunistic pathogen, infecting primarily immunocompromised individuals and cystic fibrosis (CF) patients. We previously showed that intranasal vaccination with an attenuated Salmonella enterica serovar Typhimurium strain that expresses the O antigen from an O11 serotype of P. aeruginosa protected mice from an intranasal challenge with P. aeruginosa. Administration of immune sera to naive mice at the time of infection was also able to confer protection against a lung infection (1). Here, we sought to further characterize the immune response to this vaccine and also to investigate its efficacy in clinically relevant mouse models of immunocompromise and CF. We demonstrated that both leukopenic and neutropenic mice are hypersusceptible to infection with P. aeruginosa and this is characterized by dissemination to the spleen and liver. Vaccination and administration of sera to mice at the time of infection were able to reduce the susceptibility of the immunocompromised mice and this was associated with a decreased dissemination of bacteria compared to control mice. We also investigated the adaptive immune response following vaccination. Serum antibodies were shown to persist in wild type mice for eighteen months after a single vaccination. The antibody response following vaccination was shown to be B cell and T cell, particularly CD4 cell, dependent. T cells from vaccinated mice were, however, unable to transfer protection against a P. aeruginosa challenge to naive mice. Administration of vaccine sera to CF mice was also investigated for its efficacy in preventing P. aeruginosa infection. CF mice receiving vaccine sera had increased survival compared to control mice. However, analysis of bacterial load yielded no difference between mice receiving vaccine sera and control mice. Passive vaccination of CF mice naturally infected with P. aeruginosa was able to clear the bacteria from only mice that had low anti-Pseudomonas antibody titers prior to administration of sera. Interestingly, this effect was seen with both the administration of vaccine and vector sera. This work showed the longevity of the antibody response following vaccination and further elucidates the immune response to vaccination. We also demonstrated protection from vaccination in clinically relevant models of infection.

ISBN: 9781124501222Subjects--Topical Terms:

226920
Biology, Microbiology.

Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice.
LDR:03290nmm 2200277 4500 001 309671
005 20111105132439.5
008 111212s2011 ||||||||||||||||| ||eng d
020 $a 9781124501222
035 $a (UMI)AAI3445975
035 $a AAI3445975
040 $a UMI $c UMI
100 1 $a Scarff, Jennifer Mary. $3 530975
245 1 0 $a Efficacy of a Pseudomonas aeruginosa Vaccine in Immunocompromised Mice.
300 $a 182 p.
500 $a Source: Dissertation Abstracts International, Volume: 72-04, Section: B, page: 1920.
500 $a Adviser: Joanna B. Goldberg.
502 $a Thesis (Ph.D.)--University of Virginia, 2011.
520 $a Pseudomonas aeruginosa is an important opportunistic pathogen, infecting primarily immunocompromised individuals and cystic fibrosis (CF) patients. We previously showed that intranasal vaccination with an attenuated Salmonella enterica serovar Typhimurium strain that expresses the O antigen from an O11 serotype of P. aeruginosa protected mice from an intranasal challenge with P. aeruginosa. Administration of immune sera to naive mice at the time of infection was also able to confer protection against a lung infection (1). Here, we sought to further characterize the immune response to this vaccine and also to investigate its efficacy in clinically relevant mouse models of immunocompromise and CF. We demonstrated that both leukopenic and neutropenic mice are hypersusceptible to infection with P. aeruginosa and this is characterized by dissemination to the spleen and liver. Vaccination and administration of sera to mice at the time of infection were able to reduce the susceptibility of the immunocompromised mice and this was associated with a decreased dissemination of bacteria compared to control mice. We also investigated the adaptive immune response following vaccination. Serum antibodies were shown to persist in wild type mice for eighteen months after a single vaccination. The antibody response following vaccination was shown to be B cell and T cell, particularly CD4 cell, dependent. T cells from vaccinated mice were, however, unable to transfer protection against a P. aeruginosa challenge to naive mice. Administration of vaccine sera to CF mice was also investigated for its efficacy in preventing P. aeruginosa infection. CF mice receiving vaccine sera had increased survival compared to control mice. However, analysis of bacterial load yielded no difference between mice receiving vaccine sera and control mice. Passive vaccination of CF mice naturally infected with P. aeruginosa was able to clear the bacteria from only mice that had low anti-Pseudomonas antibody titers prior to administration of sera. Interestingly, this effect was seen with both the administration of vaccine and vector sera. This work showed the longevity of the antibody response following vaccination and further elucidates the immune response to vaccination. We also demonstrated protection from vaccination in clinically relevant models of infection.
520 $a *Please refer to dissertation for footnotes.
590 $a School code: 0246.
650 4 $a Biology, Microbiology. $3 226920
690 $a 0410
710 2 $a University of Virginia. $3 492786
773 0 $t Dissertation Abstracts International $g 72-04B.
790 1 0 $a Goldberg, Joanna B., $e advisor
790 $a 0246
791 $a Ph.D.
792 $a 2011
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3445975